Dermira (NASDAQ:DERM) was upgraded by equities researchers at BidaskClub from a “sell” rating to a “hold” rating in a note issued to investors on Saturday.

A number of other analysts have also weighed in on DERM. Cantor Fitzgerald restated a “buy” rating and issued a $45.00 target price on shares of Dermira in a research report on Tuesday, September 26th. Needham & Company LLC restated a “buy” rating and issued a $46.00 target price on shares of Dermira in a research report on Sunday, September 17th. Mizuho restated a “buy” rating and issued a $43.00 target price (up previously from $40.00) on shares of Dermira in a research report on Thursday, September 7th. Zacks Investment Research upgraded shares of Dermira from a “sell” rating to a “hold” rating in a research report on Thursday, August 17th. Finally, Leerink Swann restated an “outperform” rating and issued a $41.00 target price (down previously from $47.00) on shares of Dermira in a research report on Tuesday, November 7th. Four equities research analysts have rated the stock with a sell rating, one has given a hold rating and six have assigned a buy rating to the company. Dermira currently has a consensus rating of “Hold” and a consensus target price of $43.33.

Shares of Dermira (DERM) traded down $0.05 during trading on Friday, reaching $25.55. 900,631 shares of the company’s stock were exchanged, compared to its average volume of 526,993. Dermira has a 1 year low of $21.35 and a 1 year high of $38.75. The company has a current ratio of 4.68, a quick ratio of 4.68 and a debt-to-equity ratio of 1.40.

In other news, CEO Thomas G. Wiggans sold 5,000 shares of the firm’s stock in a transaction on Thursday, November 2nd. The shares were sold at an average price of $27.52, for a total transaction of $137,600.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Eugene A. Bauer sold 7,500 shares of the firm’s stock in a transaction on Wednesday, October 11th. The shares were sold at an average price of $30.04, for a total transaction of $225,300.00. The disclosure for this sale can be found here. Insiders have sold 28,200 shares of company stock valued at $794,131 in the last ninety days. Insiders own 13.30% of the company’s stock.

Hedge funds have recently added to or reduced their stakes in the company. Platinum Investment Management Ltd. raised its stake in shares of Dermira by 28.8% during the second quarter. Platinum Investment Management Ltd. now owns 57,700 shares of the biopharmaceutical company’s stock valued at $1,681,000 after acquiring an additional 12,900 shares during the last quarter. Jennison Associates LLC raised its stake in shares of Dermira by 0.3% during the third quarter. Jennison Associates LLC now owns 2,640,740 shares of the biopharmaceutical company’s stock valued at $71,300,000 after acquiring an additional 7,746 shares during the last quarter. Renaissance Technologies LLC bought a new position in shares of Dermira during the first quarter valued at $1,023,000. Schwab Charles Investment Management Inc. raised its stake in shares of Dermira by 24.1% during the second quarter. Schwab Charles Investment Management Inc. now owns 140,495 shares of the biopharmaceutical company’s stock valued at $4,095,000 after acquiring an additional 27,259 shares during the last quarter. Finally, Vanguard Group Inc. raised its stake in shares of Dermira by 9.8% during the second quarter. Vanguard Group Inc. now owns 1,397,857 shares of the biopharmaceutical company’s stock valued at $40,735,000 after acquiring an additional 125,157 shares during the last quarter. 99.48% of the stock is owned by hedge funds and other institutional investors.

WARNING: “Dermira (DERM) Upgraded by BidaskClub to “Hold”” was first posted by American Banking News and is owned by of American Banking News. If you are reading this piece on another publication, it was copied illegally and reposted in violation of U.S. & international copyright & trademark law. The original version of this piece can be viewed at https://www.americanbankingnews.com/2017/12/02/dermira-derm-upgraded-by-bidaskclub-to-hold.html.

About Dermira

Dermira, Inc is a biopharmaceutical company. The Company is focused on the development of therapeutic solutions in medical dermatology to treat skin conditions, such as hyperhidrosis, psoriasis and acne. Its portfolio includes three late-stage product candidates: Cimzia (certolizumab pegol), glycopyrronium tosylate and olumacostat glasaretil.

Analyst Recommendations for Dermira (NASDAQ:DERM)

Receive News & Ratings for Dermira Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dermira Inc and related companies with MarketBeat.com's FREE daily email newsletter.